Unity Biotechnology, a preclinical biotech developing therapies to reduce the effects of aging, raised $85 million by offering 5 million shares at $17, the midpoint of the $16 to $18 range. Unity Biotechnology plans to list on the Nasdaq under the symbol UBX. Goldman Sachs, Morgan Stanley and Citi acted as lead managers on the deal.
